

Ulrich B Keller

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/6455915/ulrich-b-keller-publications-by-year.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

120
papers

4,542
citations

36
h-index

66
g-index

129
ext. papers

5,516
ext. citations

8.1
avg, IF

4.89
L-index

#	Paper	IF	Citations
120	Genetic alterations of the SUMO isopeptidase SENP6 drive lymphomagenesis and genetic instability in diffuse large B-cell lymphoma.. <i>Nature Communications</i> , 2022 , 13, 281	17.4	0
119	90-yttrium-ibritumomab tiuxetan as first-line treatment for follicular lymphoma: updated efficacy and safety results at an extended median follow-up of 9.6years.. <i>Annals of Hematology</i> , 2022 , 101, 781	3	0
118	Proteomic profiling reveals CDK6 upregulation as a targetable resistance mechanism for lenalidomide in multiple myeloma.. <i>Nature Communications</i> , 2022 , 13, 1009	17.4	3
117	NOXA expression drives synthetic lethality to RUNX1 inhibition in pancreatic cancer.. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2022 , 119,	11.5	3
116	Isolation of Neoantigen-Specific Human T Cell Receptors from Different Human and Murine Repertoires.. <i>Cancers</i> , 2022 , 14,	6.6	1
115	A peculiar case of primary central nervous system T-cell lymphoma with indolent behavior.. <i>Acta Neurologica Belgica</i> , 2022 ,	1.5	
114	Survey of Long-Term Experiences of Sperm Cryopreservation in Oncological and Non-Oncological Patients: Usage and Reproductive Outcomes of a Large Monocentric Cohort. <i>Frontiers in Oncology</i> , 2021 , 11, 772809	5.3	0
113	Treatment with ribociclib shows favourable immunomodulatory effects in patients with hormone receptor-positive breast cancer-findings from the RIBECCA trial.. <i>European Journal of Cancer</i> , 2021 , 162, 45-55	7.5	2
112	Significant reduced loss of bone mineral density after four vs. six cycles of R-CHOP: an analysis of the FLYER-trial. <i>Leukemia and Lymphoma</i> , 2021 , 1-9	1.9	
111	Rationale for MYC imaging and targeting in pancreatic cancer. <i>EJNMMI Research</i> , 2021 , 11, 104	3.6	3
110	A randomized phase 3 trial of autologous vs allogeneic transplantation as part of first-line therapy in poor-risk peripheral T-NHL. <i>Blood</i> , 2021 , 137, 2646-2656	2.2	10
109	High-dose glucocorticoid treatment of near-fatal bocavirus lung infection results in rapid recovery. <i>ERJ Open Research</i> , 2021 , 7,	3.5	1
108	The IMiD target CRBN determines HSP90 activity toward transmembrane proteins essential in multiple myeloma. <i>Molecular Cell</i> , 2021 , 81, 1170-1186.e10	17.6	18
107	Assessment of coronary artery disease during hospitalization for cancer treatment. <i>Clinical Research in Cardiology</i> , 2021 , 110, 200-210	6.1	2
106	The SUMO pathway in pancreatic cancer: insights and inhibition. <i>British Journal of Cancer</i> , 2021 , 124, 531-538	8.7	9
105	Polatuzumab vedotin as a salvage and bridging treatment in relapsed or refractory large B-cell lymphomas. <i>Blood Advances</i> , 2021 , 5, 2707-2716	7.8	6
104	High-affinity T-cell receptor specific for MyD88 L265P mutation for adoptive T-cell therapy of B-cell malignancies 2021 , 9,		7

103	CXCR4 hyperactivation cooperates with TCL1 in CLL development and aggressiveness. <i>Leukemia</i> , 2021 , 35, 2895-2905	10.7	2
102	Ibrutinib- and bortezomib-extended R-CHOP induction in elderly higher-risk patients newly diagnosed with diffuse large B-cell lymphoma - first analysis of toxicity and efficacy signals. <i>Leukemia and Lymphoma</i> , 2021 , 1-9	1.9	0
101	Investigation of spleen CXCR4 expression by [Ga]Pentixafor PET in a cohort of 145 solid cancer patients. <i>EJNMMI Research</i> , 2021 , 11, 77	3.6	2
100	The mTOR Inhibitor Temsirolimus Added to Rituximab Combined With Dexamethasone, Cytarabine, and Cisplatinum (R-DHAP) for the Treatment of Patients With Relapsed or Refractory DLBCL - Results From the Phase-II STORM Trial. <i>HemaSphere</i> , 2021 , 5, e636	0.3	0
99	Authentication of Primary Murine Cell Lines by a Microfluidics-Based Lab-On-Chip System. <i>Biomedicines</i> , 2020 , 8,	4.8	2
98	CXCR4-Targeted PET Imaging of Central Nervous System B-Cell Lymphoma. <i>Journal of Nuclear Medicine</i> , 2020 , 61, 1765-1771	8.9	21
97	MyD88 L265P Mutation-Specific TCR Gene Therapy for Treatment of B-Cell Lymphoma and Leukemia. <i>Blood</i> , 2020 , 136, 5-5	2.2	
96	SUMO pathway inhibition targets an aggressive pancreatic cancer subtype. <i>Gut</i> , 2020 , 69, 1472-1482	19.2	34
95	Combination of copanlisib with cetuximab improves tumor response in cetuximab-resistant patient-derived xenografts of head and neck cancer. <i>Oncotarget</i> , 2020 , 11, 3688-3697	3.3	10
94	Final Results of a Phase I/II Trial of the Combination Bendamustine and Rituximab With Temsirolimus (BeRT) in Relapsed Mantle Cell Lymphoma and Follicular Lymphoma. <i>HemaSphere</i> , 2020 , 4, e398	0.3	1
93	Targeting the ubiquitin-proteasome system in a pancreatic cancer subtype with hyperactive MYC. <i>Molecular Oncology</i> , 2020 , 14, 3048-3064	7.9	9
92	Ubiquitination and Ubiquitin-Like Modifications in Multiple Myeloma: Biology and Therapy. <i>Cancers</i> , 2020 , 12,	6.6	6
91	Age-Related Gliosis Promotes Central Nervous System Lymphoma through CCL19-Mediated Tumor Cell Retention. <i>Cancer Cell</i> , 2019 , 36, 250-267.e9	24.3	16
90	Characterization of retroviral vector derived DNA-isoforms by PCR and sequencing. <i>Journal Fur Verbraucherschutz Und Lebensmittelsicherheit</i> , 2019 , 14, 157-165	2.3	
89	MDM4 Is Targeted by 1q Gain and Drives Disease in Burkitt Lymphoma. <i>Cancer Research</i> , 2019 , 79, 3125-3138	10.3	8
88	Side Effects of CXCR4-Directed Endoradiotherapy with Pentixather Before Hematopoietic Stem Cell Transplantation. <i>Journal of Nuclear Medicine</i> , 2019 , 60, 1399-1405	8.9	17
87	PiggyBac transposon tools for recessive screening identify B-cell lymphoma drivers in mice. <i>Nature Communications</i> , 2019 , 10, 1415	17.4	25
86	SDF1-induced chemotaxis of JAK2-V617F-positive cells is dependent on Bruton tyrosine kinase and its downstream targets PI3K/AKT, PLC β and RhoA. <i>Haematologica</i> , 2019 , 104, e288-e292	6.6	3

85	Towards quantitative imaging biomarkers of tumor dissemination: A multi-scale parametric modeling of multiple myeloma. <i>Medical Image Analysis</i> , 2019 , 57, 214-225	15.4	4
84	The SUMO Isopeptidase SENP6 Functions as a Rheostat of Chromatin Residency in Genome Maintenance and Chromosome Dynamics. <i>Cell Reports</i> , 2019 , 29, 480-494.e5	10.6	18
83	Activated gp130 signaling selectively targets B cell differentiation to induce mature lymphoma and plasmacytoma. <i>JCI Insight</i> , 2019 , 4,	9.9	5
82	The IMiD-Target Cereblon Determines Transmembrane Protein Quality Control Promoting Tumor Metabolism. <i>Blood</i> , 2019 , 134, 314-314	2.2	
81	Four versus six cycles of CHOP chemotherapy in combination with six applications of rituximab in patients with aggressive B-cell lymphoma with favourable prognosis (FLYER): a randomised, phase 3, non-inferiority trial. <i>Lancet, The</i> , 2019 , 394, 2271-2281	40	85
80	Clinical presentation and characteristics of lymphoma in the head and neck region. <i>Head & Face Medicine</i> , 2019 , 15, 1	2.4	33
79	Autologous Stem Cell Transplantation for Patients with Early Progression of Follicular Lymphoma: A Follow-Up Study of 2 Randomized Trials from the German Low Grade Lymphoma Study Group. <i>Biology of Blood and Marrow Transplantation</i> , 2018 , 24, 1172-1179	4.7	50
78	REGGAE: a novel approach for the identification of key transcriptional regulators. <i>Bioinformatics</i> , 2018 , 34, 3503-3510	7.2	6
77	CXCR4-directed theranostics in oncology and inflammation. <i>Annals of Nuclear Medicine</i> , 2018 , 32, 503-514.	11.5	61
76	Dual Targeting of Acute Leukemia and Supporting Niche by CXCR4-Directed Theranostics. <i>Theranostics</i> , 2018 , 8, 369-383	12.1	42
75	Radiotherapy (RT) to bulky (B) and extralymphatic (E) disease in combination with 6xR-CHOP-14 or R-CHOP-21 in young good-prognosis DLBCL patients: Results of the 2x2 randomized UNFOLDER trial of the DSHNHL/GLA.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 7574-7574	2.2	14
74	Design, synthesis and biological activity of N-phenylsubstituted-7H-pyrrolo[2,3-d]pyrimidin-4-amines as dual inhibitors of aurora kinase A and epidermal growth factor receptor kinase. <i>Journal of Enzyme Inhibition and Medicinal Chemistry</i> , 2018 , 33, 71-81	5.6	11
73	Rituximab With Involved Field Irradiation for Early-stage Nodal Follicular Lymphoma: Results of the MIR Study. <i>HemaSphere</i> , 2018 , 2, e160	0.3	23
72	Non-Hodgkin Lymphoma Secondary to Hodgkin Lymphoma in an Adult Patient With Nijmegen Breakage Syndrome. <i>HemaSphere</i> , 2018 , 2, e140	0.3	
71	Cancer clinical trials - Survey evaluating patient participation and acceptance in a university-based Comprehensive Cancer Center (CCC). <i>Clinical and Translational Radiation Oncology</i> , 2018 , 13, 44-49	4.6	3
70	PET imaging of chemokine receptor CXCR4 in patients with primary and recurrent breast carcinoma. <i>EJNMMI Research</i> , 2018 , 8, 90	3.6	15
69	Progression-free survival of early interim PET-positive patients with advanced stage Hodgkin lymphoma treated with BEACOPP alone or in combination with rituximab (HD18): an open-label, international, randomised phase 3 study by the German Hodgkin Study Group. <i>Lancet Oncology, The</i> , 2017 , 18, 454-463	21.7	62
68	HSP90 promotes Burkitt lymphoma cell survival by maintaining tonic B-cell receptor signaling. <i>Blood</i> , 2017 , 129, 598-608	2.2	16

67	Clinical responses to adoptive T-cell transfer can be modeled in an autologous immune-humanized mouse model. <i>Nature Communications</i> , 2017 , 8, 707	17.4	82
66	Whole-brain radiotherapy or autologous stem-cell transplantation as consolidation strategies after high-dose methotrexate-based chemoimmunotherapy in patients with primary CNS lymphoma: results of the second randomisation of the International Extranodal Lymphoma Study Group-32 phase 2 trial. <i>Lancet Haematology, the</i> , 2017 , 4, e510-e523	14.6	157
65	Optimization of rituximab for the treatment of DLBCL: increasing the dose for elderly male patients. <i>British Journal of Haematology</i> , 2017 , 179, 410-420	4.5	28
64	Azacitidine combined with the selective FLT3 kinase inhibitor crenolanib disrupts stromal protection and inhibits expansion of residual leukemia-initiating cells in -ITD AML with concurrent epigenetic mutations. <i>Oncotarget</i> , 2017 , 8, 108738-108759	3.3	11
63	Pathogenesis and therapeutic targeting of aberrant MYC expression in haematological cancers. <i>British Journal of Haematology</i> , 2017 , 179, 724-738	4.5	28
62	Response assessment with the CXCR4-directed positron emission tomography tracer [Ga]Pentixafor in a patient with extranodal marginal zone lymphoma of the orbital cavities. <i>EJNMMI Research</i> , 2017 , 7, 51	3.6	19
61	High-dose methotrexate-based immuno-chemotherapy for elderly primary CNS lymphoma patients (PRIMAIN study). <i>Leukemia</i> , 2017 , 31, 846-852	10.7	88
60	[Lu]pentixather: Comprehensive Preclinical Characterization of a First CXCR4-directed Endoradiotherapeutic Agent. <i>Theranostics</i> , 2017 , 7, 2350-2362	12.1	49
59	Functional imaging in combination with mutation status aids prediction of response to inhibiting B-cell receptor signaling in lymphoma. <i>Oncotarget</i> , 2017 , 8, 78917-78929	3.3	2
58	Mobile Health in Oncology: A Patient Survey About App-Assisted Cancer Care. <i>JMIR MHealth and UHealth</i> , 2017 , 5, e81	5.5	57
57	Targeted positron emission tomography imaging of CXCR4 expression in patients with acute myeloid leukemia. <i>Haematologica</i> , 2016 , 101, 932-40	6.6	37
56	USP9X stabilizes XIAP to regulate mitotic cell death and chemoresistance in aggressive B-cell lymphoma. <i>EMBO Molecular Medicine</i> , 2016 , 8, 851-62	12	37
55	Immunomodulatory drugs disrupt the cereblon-CD147-MCT1 axis to exert antitumor activity and teratogenicity. <i>Nature Medicine</i> , 2016 , 22, 735-43	50.5	110
54	First Experience with Chemokine Receptor CXCR4-Targeted PET Imaging of Patients with Solid Cancers. <i>Journal of Nuclear Medicine</i> , 2016 , 57, 741-6	8.9	77
53	First-in-Human Experience of CXCR4-Directed Endoradiotherapy with ¹⁷⁷ Lu- and ⁹⁰ Y-Labeled Pentixather in Advanced-Stage Multiple Myeloma with Extensive Intra- and Extramedullary Disease. <i>Journal of Nuclear Medicine</i> , 2016 , 57, 248-51	8.9	137
52	Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: results of the first randomisation of the International Extranodal Lymphoma Study Group-32 (IELSG32) phase 2 trial. <i>Lancet Haematology, the</i> , 2016 , 3, e217-27	14.6	288
51	High-dose chemotherapy with autologous haemopoietic stem cell transplantation for newly diagnosed primary CNS lymphoma: a prospective, single-arm, phase 2 trial. <i>Lancet Haematology, the</i> , 2016 , 3, e388-97	14.6	93
50	Direct Parametric Image Reconstruction in Reduced Parameter Space for Rapid Multi-Tracer PET Imaging. <i>IEEE Transactions on Medical Imaging</i> , 2015 , 34, 1498-1512	11.7	20

49	Biodistribution and radiation dosimetry for the chemokine receptor CXCR4-targeting probe ⁶⁸ Ga-pentixafor. <i>Journal of Nuclear Medicine</i> , 2015 , 56, 410-6	8.9	84
48	Everolimus maintenance in patients with mantle cell lymphoma not eligible for intensive therapy: results of a prematurely closed phase 2 study. <i>Leukemia and Lymphoma</i> , 2015 , 56, 3227-9	1.9	4
47	In vivo molecular imaging of chemokine receptor CXCR4 expression in patients with advanced multiple myeloma. <i>EMBO Molecular Medicine</i> , 2015 , 7, 477-87	12	144
46	Disclosing the CXCR4 expression in lymphoproliferative diseases by targeted molecular imaging. <i>Theranostics</i> , 2015 , 5, 618-30	12.1	135
45	Lymphomagenic CARD11/BCL10/MALT1 signaling drives malignant B-cell proliferation via cooperative NF- κ B and JNK activation. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015 , 112, E7230-8	11.5	51
44	Preclinical Evaluation of CD40-Directed Immunotherapy in B-Cell Lymphoma Using [18 F]Fluorothymidine-PET. <i>Advances in Molecular Imaging</i> , 2015 , 05, 17-28	0.3	1
43	In vivo hematopoietic Myc activation directs a transcriptional signature in endothelial cells within the bone marrow microenvironment. <i>Oncotarget</i> , 2015 , 6, 21827-39	3.3	
42	An adult patient with Nijmegen Breakage Syndrome and Hodgkin's Lymphoma. <i>BMC Hematology</i> , 2014 , 14, 2	2.5	4
41	Novel approach of MALDI drug imaging, immunohistochemistry, and digital image analysis for drug distribution studies in tissues. <i>Analytical Chemistry</i> , 2014 , 86, 10568-75	7.8	34
40	Myc-induced SUMOylation is a therapeutic vulnerability for B-cell lymphoma. <i>Blood</i> , 2014 , 124, 2081-90	2.2	54
39	Positron emission tomographic monitoring of dual phosphatidylinositol-3-kinase and mTOR inhibition in anaplastic large cell lymphoma. <i>OncoTargets and Therapy</i> , 2014 , 7, 789-98	4.4	11
38	Combination therapy with brentuximab vedotin and cisplatin/cytarabine in a patient with primarily refractory anaplastic lymphoma kinase positive anaplastic large cell lymphoma. <i>OncoTargets and Therapy</i> , 2014 , 7, 1123-7	4.4	7
37	Optimization of rituximab for the treatment of diffuse large B-cell lymphoma (II): extended rituximab exposure time in the SMARTE-R-CHOP-14 trial of the german high-grade non-Hodgkin lymphoma study group. <i>Journal of Clinical Oncology</i> , 2014 , 32, 4127-33	2.2	64
36	BET and HDAC inhibitors induce similar genes and biological effects and synergize to kill in Myc-induced murine lymphoma. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014 , 111, E2721-30	11.5	163
35	Disruption of the PRKCD-FBXO25-HAX-1 axis attenuates the apoptotic response and drives lymphomagenesis. <i>Nature Medicine</i> , 2014 , 20, 1401-9	50.5	36
34	Effectiveness and tolerability of ipilimumab: experiences from 198 patients included in a named-patient program in various daily-practice settings and multiple institutions. <i>Journal of Immunotherapy</i> , 2014 , 37, 374-81	5	19
33	GP130 activation induces myeloma and collaborates with MYC. <i>Journal of Clinical Investigation</i> , 2014 , 124, 5263-74	15.9	27
32	Week one FLT-PET response predicts complete remission to R-CHOP and survival in DLBCL. <i>Oncotarget</i> , 2014 , 5, 4050-9	3.3	20

31	Synthetic lethal metabolic targeting of cellular senescence in cancer therapy. <i>Nature</i> , 2013 , 501, 421-5	50.4	342
30	[18F]FLT is superior to [18F]FDG for predicting early response to antiproliferative treatment in high-grade lymphoma in a dose-dependent manner. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2013 , 40, 34-43	8.8	33
29	Myeloablative anti-CD20 radioimmunotherapy +/- high-dose chemotherapy followed by autologous stem cell support for relapsed/refractory B-cell lymphoma results in excellent long-term survival. <i>Oncotarget</i> , 2013 , 4, 899-910	3.3	15
28	Molecular imaging for early prediction of response to Sorafenib treatment in sarcoma. <i>American Journal of Nuclear Medicine and Molecular Imaging</i> , 2013 , 4, 70-9	2.2	9
27	NIPA Deficiency Leads To Acceleration Of The Lymphoma Development In E μ Myc Mice. <i>Blood</i> , 2013 , 122, 3681-3681	2.2	
26	Proteinkinase C-Inhibitors Mitigate Microenvironment-Mediated Survival Of CLL Cells and Sensitise Malignant B Cells To Cytotoxic Drugs. <i>Blood</i> , 2013 , 122, 669-669	2.2	
25	Cks1 promotion of S phase entry and proliferation is independent of p27Kip1 suppression. <i>Molecular and Cellular Biology</i> , 2012 , 32, 2416-27	4.8	7
24	FLT-PET is superior to FDG-PET for very early response prediction in NPM-ALK-positive lymphoma treated with targeted therapy. <i>Cancer Research</i> , 2012 , 72, 5014-24	10.1	35
23	Efficacy of repeat myeloablative chemotherapy with autologous stem-cell support in multiple myeloma. <i>Therapeutic Advances in Hematology</i> , 2012 , 3, 81-8	5.7	
22	Cks1 is required for tumor cell proliferation but not sufficient to induce hematopoietic malignancies. <i>PLoS ONE</i> , 2012 , 7, e37433	3.7	14
21	Ipilimumab use in a named-patient program in metastatic melanoma: Experiences in 185 German patients.. <i>Journal of Clinical Oncology</i> , 2012 , 30, e19031-e19031	2.2	
20	Stromal pleiotrophin regulates repopulation behavior of hematopoietic stem cells. <i>Blood</i> , 2011 , 118, 2712-22	2.2	29
19	Therapeutic implications for the induced levels of Chk1 in Myc-expressing cancer cells. <i>Clinical Cancer Research</i> , 2011 , 17, 7067-79	12.9	108
18	The direct Myc target Pim3 cooperates with other Pim kinases in supporting viability of Myc-induced B-cell lymphomas. <i>Oncotarget</i> , 2011 , 2, 448-60	3.3	38
17	Aurora kinase inhibition overcomes cetuximab resistance in squamous cell cancer of the head and neck. <i>Oncotarget</i> , 2011 , 2, 599-609	3.3	60
16	Skp2 directs Myc-mediated suppression of p27Kip1 yet has modest effects on Myc-driven lymphomagenesis. <i>Molecular Cancer Research</i> , 2010 , 8, 353-62	6.6	22
15	Aurora kinases A and B are up-regulated by Myc and are essential for maintenance of the malignant state. <i>Blood</i> , 2010 , 116, 1498-505	2.2	174
14	Myc suppression of Nfkb2 accelerates lymphomagenesis. <i>BMC Cancer</i> , 2010 , 10, 348	4.8	21

13	Oncologist@/haematologist@ view on the roles of pathologists for molecular targeted cancer therapy. <i>Journal of Cellular and Molecular Medicine</i> , 2010 , 14, 805-17	5.6	2
12	Loss of Therapy-Induced Senescence in Myc-Driven Lymphomas Compromises Treatment Outcome In Vivo.. <i>Blood</i> , 2009 , 114, 1686-1686	2.2	
11	Myc targets Cks1 to provoke the suppression of p27Kip1, proliferation and lymphomagenesis. <i>EMBO Journal</i> , 2007 , 26, 2562-74	13	78
10	Myc Promotes Tumorigenesis by Suppressing Nfkb2.. <i>Blood</i> , 2006 , 108, 1422-1422	2.2	
9	Nfkb 1 is dispensable for Myc-induced lymphomagenesis. <i>Oncogene</i> , 2005 , 24, 6231-40	9.2	32
8	Targeting ornithine decarboxylase in Myc-induced lymphomagenesis prevents tumor formation. <i>Cancer Cell</i> , 2005 , 7, 433-44	24.3	157
7	Endothelial-like cells expanded from CD34+ blood cells improve left ventricular function after experimental myocardial infarction. <i>FASEB Journal</i> , 2005 , 19, 992-4	0.9	95
6	Mnt loss triggers Myc transcription targets, proliferation, apoptosis, and transformation. <i>Molecular and Cellular Biology</i> , 2004 , 24, 1560-9	4.8	79
5	Id2 is dispensable for myc-induced lymphomagenesis. <i>Cancer Research</i> , 2004 , 64, 7296-301	10.1	18
4	Sustained expansion and transgene expression of coagulation factor VIII-transduced cord blood-derived endothelial progenitor cells. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2003 , 23, 2266-72	9.4	27
3	Targeting of hematopoietic progenitor cells with MR contrast agents. <i>Radiology</i> , 2003 , 228, 760-7	20.5	179
2	c-Myc augments gamma irradiation-induced apoptosis by suppressing Bcl-XL. <i>Molecular and Cellular Biology</i> , 2003 , 23, 7256-70	4.8	115
1	Regulation of hematopoietic growth factor production by genetically modified human bone marrow stromal cells expressing interleukin-1beta antisense RNA. <i>Journal of Interferon and Cytokine Research</i> , 2001 , 21, 851-60	3.5	3